Abstract
The first successful therapeutic iron chelator was desferrioxamine which was introduced in the late 1960’s by Ciba (now Novartis). Desferrioxamine has been an extremely successful compound having received the MMW “Pharmaceutical of the year” award for 1991. It is a life saving and a life – prolonging drug which improves the quality of life. However it is not orally active and its administration is both uncomfortable and expensive.
Over the past twenty years there has been a growing interest in the orally active iron chelators, deferiprone and exjade, both having been extensively studied. The ability of these compounds to mobilize iron from the heart and endocrine tissue has presented the clinician with some advantages over desferrioxamine. Other orally active iron chelators are currently under development and one, FBS0701 is in clinical trial.
The critical features necessary for the design of therapeutically useful iron chelators is presented in this review, together with recent studies devoted to the design of such chelators. This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes.
Keywords: Iron chelators, hydroxamates, desferrioxamine, hydroxypyridinones, deferiprone, exjade
Current Medicinal Chemistry
Title:Chelating Agents for the Treatment of Systemic Iron Overload
Volume: 19 Issue: 17
Author(s): Y. Ma, T. Zhou, X. Kong and R. C. Hider
Affiliation:
Keywords: Iron chelators, hydroxamates, desferrioxamine, hydroxypyridinones, deferiprone, exjade
Abstract: The first successful therapeutic iron chelator was desferrioxamine which was introduced in the late 1960’s by Ciba (now Novartis). Desferrioxamine has been an extremely successful compound having received the MMW “Pharmaceutical of the year” award for 1991. It is a life saving and a life – prolonging drug which improves the quality of life. However it is not orally active and its administration is both uncomfortable and expensive.
Over the past twenty years there has been a growing interest in the orally active iron chelators, deferiprone and exjade, both having been extensively studied. The ability of these compounds to mobilize iron from the heart and endocrine tissue has presented the clinician with some advantages over desferrioxamine. Other orally active iron chelators are currently under development and one, FBS0701 is in clinical trial.
The critical features necessary for the design of therapeutically useful iron chelators is presented in this review, together with recent studies devoted to the design of such chelators. This newly emerging range of iron chelators will enable clinicians to apply iron chelation methodology to other disease states and to begin to design personalised chelation regimes.
Export Options
About this article
Cite this article as:
Ma Y., Zhou T., Kong X. and C. Hider R., Chelating Agents for the Treatment of Systemic Iron Overload, Current Medicinal Chemistry 2012; 19 (17) . https://dx.doi.org/10.2174/092986712800609724
DOI https://dx.doi.org/10.2174/092986712800609724 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Effects of Fibrates: An Overview
Current Medicinal Chemistry Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology The Epidemiology of Adiposity and Dementia
Current Alzheimer Research Selenium-Enriched Yeast: As Selenium Source for Nutritional Purpose
Current Nutrition & Food Science Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Pharmacogenetics and Statin Treatment: Reality or Theory?
Current Vascular Pharmacology Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner
Anti-Cancer Agents in Medicinal Chemistry The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Sterol 14α-Demethylase from Trypanosomatidae Parasites as a Promising Target for Designing New Antiparasitic Agents
Current Topics in Medicinal Chemistry Direct Cardiac Reprogramming with Engineered miRNA Scaffolds
Current Pharmaceutical Design <i>Qiliqiangxin</i> Prescription Promotes Angiogenesis of Hypoxic Primary Rat Cardiac Microvascular Endothelial Cells via Regulating miR-21 Signaling
Current Pharmaceutical Design The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry